Alps Advisors Inc Arbutus Biopharma Corp Transaction History

Alps Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$2.23 - $3.1 $1,955 - $2,718	877 Added 0.83%	107,107 $324,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $46,512 - $69,403	24,352 Added 29.74%	106,230 $247,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $11,930 - $18,276	-6,346 Reduced 7.19%	81,878 $156,000
Q2 2022 Aug 11, 2022	SELL	$1.98 - $3.17 $127,785 - $204,585	-64,538 Reduced 42.25%	88,224 $239,000
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $9,157 - $15,060	-3,784 Reduced 2.42%	152,762 $455,000
Q4 2021 Feb 09, 2022	BUY	$3.11 - $4.61 $486,858 - $721,677	156,546 New	156,546 $609,000
Q2 2019 Aug 07, 2019	SELL	$1.46 - $4.44 $195,717 - $595,195	-134,053 Closed	0 $0
Q1 2019 May 01, 2019	BUY	$3.41 - $4.57 $20,514 - $27,493	6,016 Added 4.7%	134,053 $480,000
Q4 2018 Feb 04, 2019	BUY	$3.5 - $9.66 $448,129 - $1.24 Million	128,037 New	128,037 $490,000

157

99.6M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $507M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.